Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, ...
Early and Consistent Decreases in P-tau 217 Plasma Levels Were Associated with Improvements in Cognition, Function, and Brain Atrophy Measures MCI Subjects Receiving Valiltramiprosate Showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results